Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olopatadine 0.2% QD vs 0.1% BID in Allergic Conjunctivitis
NCT02322216Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Dec 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of olopatadine in allergic conjunctivitis (AC), sponsored by Alcon Inc.. Started Dec 2014; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02322216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322216.